Leerink Partners Downgrades Affimed Therapeutics (AFMD) to Market Perform

August 12, 2016 7:41 AM

Leerink Partners downgraded Affimed Therapeutics (NASDAQ: AFMD) from Outperform to Market Perform with a price target of $3.00 (from $8.00).Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found